At present, in the clinical treatment of T2DM, most drugs target insulin and glucose transporters, such as metformin, thiazolidinediones, GLP-1 receptor agonists, SGLT-1 inhibitors, etc., while few drugs target digestive enzymes. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.